Rivaroxaban (Xarelto, BAY59-7939) + Standard of care
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Deep Vein Thrombosis
Conditions
Deep Vein Thrombosis, Venous Thrombosis
Trial Timeline
Jun 1, 2012 → Jul 1, 2015
NCT ID
NCT01619007About Rivaroxaban (Xarelto, BAY59-7939) + Standard of care
Rivaroxaban (Xarelto, BAY59-7939) + Standard of care is a pre-clinical stage product being developed by Bayer for Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01619007. Target conditions include Deep Vein Thrombosis, Venous Thrombosis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01619007 | Pre-clinical | Completed |
| NCT01947959 | Pre-clinical | Completed |
Competing Products
20 competing products in Deep Vein Thrombosis